Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Fostamatinib Skates Through OSKIRA-1 With Mixed Results

Apr 05 2013

• By Emily Hayes

Related Content

Oral Dosing May Not Be Enough To Win Speedy Adoption Of Pfizer’s RA Pill <em>Xeljanz</em>

Nov 12 2012

AZ Continues To Buy Pipeline With $100M Rigel Deal

Feb 16 2010

With Much Riding On Fostamatinib, Rigel Awaits The Phase III Results

Mar 04 2013

Related Companies

AstraZeneca PLC

Rigel Pharmaceuticals, Inc.

Pfizer Inc.

Abbott

Additional Topics

Clinical Trials

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window